Compare Celsius Holdings, Inc. (CELH) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs Smith & Nephew plc — how do they compare? Celsius Holdings, Inc. trades at $30.27 (market cap $7.71B), while Smith & Nephew plc trades at $30.73 (market cap $12.40B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.62% dividend while Celsius Holdings, Inc. pays none. Which is the better fit depends on your goals.
| CELH | SNN | |
|---|---|---|
Market Cap | $7.71B | $12.40B |
Sector | Consumer Staples | Health |
52-Week High | $64.86 | $38.70 |
52-Week Low | $27.75 | $28.73 |
Enterprise Value | $9.58B | $15.17B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Celsius Holdings (CELH) trades at $29.83, down 2.52% on the day, amid bearish technical signals despite strong analyst support. The stock shows robust revenue growth, with 2025 sales reaching $2.52B, though net margins have compressed to 4.29%. Recent quarters consistently beat EPS estimates, but cash flow turned negative due to heavy investing activity. Legal investigations and competitive pressures weigh on sentiment, while a $52.30 consensus price target implies significant upside.
Outlook remains bifurcated: high growth potential and international expansion contrast with margin pressure and litigation risks. Investors face a volatile growth story where execution on profitability and market share gains will dictate performance. The stock's high P/E of 71.16 demands sustained earnings acceleration to justify valuation.
SNN trades at $31.08, up 1.24% with a bullish technical signal. The company shows improving fundamentals with 2024 revenue of $5.81B and net income of $412M, while recent earnings beat expectations. Strong cash flow generation and new product launches in robotics and wound care support growth. Analyst consensus is mixed with 27% buy ratings but majority holds.
Outlook remains positive with projected revenue growth and margin expansion, though recent earnings misses and elevated valuation metrics pose risks. The stock's technical strength and fundamental recovery present opportunity, but investor caution is warranted given mixed analyst sentiment and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
